EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

CAR-T: What Is Next?

Yi-Ju Chen, Bams Abila, Yasser Mostafa Kamel

Cancers · 21.01.2023 · 15 (3) · 663

DOI: 10.3390/cancers15030663 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 21.01.2023. Verfasst von Yi-Ju Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Cancer & Pharmaceutical Sciences, Faculty of Life & Sciences & Medicine, King's College, London SE1 9NH, UK. Die Arbeit wurde bisher 241-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The year 2017 was marked by the Food and Drug Administration (FDA) approval of the first two chimeric antigen receptor-T (CAR-T) therapies. The approved indications were for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and for the treatment of patients up to 25 years of age with acute lymphoblastic leukemia (ALL) that is refractory or in a second or later relapse. Since then, extensive research activities have been ongoing globally on different hematologic and solid tumors to assess the safety and efficacy of CAR-T therapy for these diseases. Limitations to CAR-T therapy became apparent from, e.g., the relapse in up to 60% of patients and certain side effects such as cytokine release syndrome (CRS). This led to extensive clinical activities aimed at overcoming these obstacles, so that the use of CAR-T therapy can be expanded. Attempts to improve on efficacy and safety include changing the CAR-T administration schedule, combining it with chemotherapy, and the development of next-generation CAR-T therapies, e.g., through the use of CAR-natural killer (CAR-NK) and CAR macrophages (CAR-Ms). This review will focus on new CAR-T treatment strategies in hematologic malignancies, clinical trials aimed at improving efficacy and addressing side effects, the challenges that CAR-T therapy faces in solid tumors, and the ongoing research aimed at overcoming these challenges.

Schlagwörter

Stichwörter der Autor:innen

CAR macrophages (CAR-Ms)CAR-NKCAR-T therapyCAR-natural killerchimeric antigen receptor-t

Autor:innen und Institutionen

  • School of Cancer & Pharmaceutical Sciences, Faculty of Life & Sciences & Medicine, King's College, London SE1 9NH, UK.

Zitieren

APA

Chen, Y. J., Abila, B., & Mostafa Kamel, Y. (2023). CAR-T: What Is Next?. Cancers, 15(3), 663. https://doi.org/10.3390/cancers15030663

Vancouver

Chen YJ, Abila B, Mostafa Kamel Y. CAR-T: What Is Next?. Cancers. 2023;15(3):663. doi:10.3390/cancers15030663

BibTeX
@article{Chen2023,
  author = {Chen, Yi-Ju and Abila, Bams and Mostafa Kamel, Yasser},
  title = {CAR-T: What Is Next?},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {3},
  pages = {663},
  doi = {10.3390/cancers15030663}
}
Kostenlos starten →